Researchers reveal how a topical drug called resiquimod led to total remission for some patients with a cutaneous T cell lymphoma - a rare skin lymphoma.

Phase 1 trial first to show topical therapy causes systemic immune response, and may eradicate cancerous cells from treated and untreated lesionsResults of a phase one trial show that an...